Pain at Presentation and Survival in Hepatocellular Carcinoma

Carr, Brian I.; Pujol, L.

doi:10.1016/j.jpain.2010.01.265

Cited by 20 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that the presence of pain and high pain intensity are important predictors of clinical outcomes in cancer patients 42‐48. Our study extends those findings to indicate that high pain variability with worsening pain intensity represents an adverse prognostic factor that may indicate disease progression, such as increased tumor size or more aggressive tumor characteristics.…”

Section: Discussionsupporting

confidence: 83%

A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer

Zhu

Davis

Stuver

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND: Although pain is common among patients with advanced cancer, little is known about longitudinal variability in pain intensity. For this report, the authors examined variability in pain intensity over 24 months among ambulatory patients with advanced stage cancers, associations between patient characteristics and within‐patient pain variability, and the relation of pain variability to overall survival. METHODS: The sample comprised 949 patients with solid tumors who received care and reported pain scores in at least 3 different months within 24 months of their initial stage IV diagnosis during the period from 2004 to 2006. Pain intensity was measured using a scale ranging from 0 (no pain) to 10 (worst pain). Pain variability was defined as the standard deviation of the maximum monthly pain scores and was dichotomized at the 50th percentile into high and low variability groups. RESULTS: Considerable between‐patient differences in pain variability (range, 0‐5.77) were observed. Nonwhites, patients with a stage IV cancer diagnosed within the previous 3 months, and those with moderate or severe pain at baseline were more likely to experience high pain variability. Although patients with head and neck cancer generally had the highest pain variability, the intensity of their pain typically decreased over the disease course. High pain variability with worsening pain trajectory was associated with increased risk of death. CONCLUSIONS: Longitudinally, pain intensity was highly variable among patients with stage IV cancer. Minority patients, newly diagnosed patients, patients with head and neck cancer, and patients with moderate or severe pain at baseline were at higher risk of large fluctuations in pain intensity. Cancer 2012. © 2012 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 83%

A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer

Zhu

Davis

Stuver

et al. 2012

Cancer

View full text Add to dashboard Cite

show abstract

“… 457 A few studies have investigated the prevalence of pain in HCC patients, which is reported to range from 22% to 66.8%. 455 , 458 , 459 Therefore, pain management should be considered an important aspect of palliative care for HCC patients. As most HCC patients have chronic liver disease and/or liver cirrhosis, their drug metabolism may be altered according to the degree of liver dysfunction.…”

Section: Drug Treatment For Cancer Pain In Hccmentioning

confidence: 99%

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

2015

View full text Add to dashboard Cite

The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.

show abstract

“…The prevalence of pain in cancer patients ranges from 45% to 53% ( 454 , 455 , 456 ), and early aggressive palliative care including pain management could improve survival in lung cancer patients ( 457 ). A few studies have investigated the prevalence of pain in HCC patients, which is reported to range from 22% to 66.8% ( 455 , 458 , 459 ). Therefore, pain management should be considered an important aspect of palliative care for HCC patients.…”

Section: Drug Treatment For Cancer Pain In Hccmentioning

confidence: 99%

2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Park¹,

Lee²,

Suh³

et al. 2015

Korean J Radiol

162

View full text Add to dashboard Cite

show abstract

Pain at Presentation and Survival in Hepatocellular Carcinoma

Cited by 20 publications

References 16 publications

A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer

A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About